Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The company's management team will engage in a fireside chat on Thursday, February 6, 2025, at 10:00 am ET and conduct one-on-one meetings throughout the conference, which runs from February 5-6, 2025, in New York, NY.
The biopharmaceutical company, which specializes in developing and commercializing novel treatments for gastrointestinal (GI) diseases, will provide a live webcast of the event. Interested parties can access both the live presentation and an archived recording through the Events & Presentations section of Phathom's website. The recording will remain available for 90 days after the event's conclusion.
Phathom Pharmaceuticals (Nasdaq: PHAT) ha annunciato la sua prossima partecipazione alla Guggenheim Securities SMID Cap Biotech Conference. Il team di gestione dell'azienda parteciperà a una conversazione informale giovedì 6 febbraio 2025, alle 10:00 ET e svolgerà incontri individuali durante la conferenza, che si terrà dal 5 al 6 febbraio 2025 a New York, NY.
La compagnia biofarmaceutica, specializzata nello sviluppo e nella commercializzazione di trattamenti innovativi per le malattie gastrointestinali (GI), fornirà una diretta streaming dell'evento. Le parti interessate possono accedere sia alla presentazione in diretta che a una registrazione archiviata attraverso la sezione Eventi & Presentazioni del sito web di Phathom. La registrazione rimarrà disponibile per 90 giorni dopo la conclusione dell'evento.
Phathom Pharmaceuticals (Nasdaq: PHAT) ha anunciado su próxima participación en la Guggenheim Securities SMID Cap Biotech Conference. El equipo de gestión de la compañía participará en una charla informal el jueves 6 de febrero de 2025, a las 10:00 am ET y llevará a cabo reuniones individuales durante la conferencia, que se llevará a cabo del 5 al 6 de febrero de 2025 en Nueva York, NY.
La compañía biofarmacéutica, que se especializa en el desarrollo y comercialización de tratamientos novedosos para las enfermedades gastrointestinales (GI), ofrecerá una transmisión en vivo del evento. Las partes interesadas pueden acceder tanto a la presentación en vivo como a una grabación archivada a través de la sección de Eventos y Presentaciones del sitio web de Phathom. La grabación permanecerá disponible durante 90 días después de la conclusión del evento.
Phathom Pharmaceuticals (Nasdaq: PHAT)가 Guggenheim Securities SMID Cap Biotech Conference에 참여할 예정이라고 발표했습니다. 회사의 경영진 팀은 2025년 2월 6일 목요일 오전 10:00 ET에 편안한 대담에 참여하며, 2025년 2월 5일부터 6일까지 뉴욕, NY에서 열리는 컨퍼런스 동안 일대일 미팅을 진행합니다.
이 바이오 제약 회사는 위장관(GI) 질환에 대한 혁신적인 치료제를 개발하고 상용화하는 전문 기업으로, 이벤트의 생중계를 제공합니다. 관계자는 Phathom 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 실시간 프레젠테이션과 보관된 녹음을 모두 접속할 수 있습니다. 녹음은 이벤트 종료 후 90일 동안 이용 가능합니다.
Phathom Pharmaceuticals (Nasdaq: PHAT) a annoncé sa prochaine participation à la Guggenheim Securities SMID Cap Biotech Conference. L'équipe de direction de l'entreprise participera à une discussion informelle le jeudi 6 février 2025, à 10h00 ET et mènera des réunions individuelles tout au long de la conférence, qui se déroulera du 5 au 6 février 2025 à New York, NY.
Cette entreprise biopharmaceutique, qui se spécialise dans le développement et la commercialisation de traitements novateurs pour les maladies gastro-intestinales (GI), proposera une diffusion en direct de l'événement. Les parties intéressées peuvent accéder à la fois à la présentation en direct et à un enregistrement archivé via la section Événements et Présentations du site Web de Phathom. L'enregistrement restera disponible pendant 90 jours après la fin de l'événement.
Phathom Pharmaceuticals (Nasdaq: PHAT) hat seine bevorstehende Teilnahme an der Guggenheim Securities SMID Cap Biotech Conference angekündigt. Das Managementteam des Unternehmens wird am Donnerstag, den 6. Februar 2025, um 10:00 Uhr ET an einem informellen Gespräch teilnehmen und während der Konferenz, die vom 5. bis 6. Februar 2025 in New York, NY, stattfindet, Einzelgespräche führen.
Das biopharmazeutische Unternehmen, das auf die Entwicklung und Kommerzialisierung neuartiger Behandlungen für gastrointestinale (GI) Erkrankungen spezialisiert ist, wird eine Live-Übertragung der Veranstaltung bereitstellen. Interessierte können sowohl die Live-Präsentation als auch eine aufgezeichnete Version über den Bereich Veranstaltungen & Präsentationen auf der Website von Phathom abrufen. Die Aufnahme wird 90 Tage nach Abschluss der Veranstaltung verfügbar sein.
- None.
- None.
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET.
Company management will also participate in one-on-one meetings during the conference, which will run from February 5-6, 2025, in New York, NY.
To access the live webcast and archived recording of the event, visit the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When is Phathom Pharmaceuticals (PHAT) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How long will the recording of PHAT's Guggenheim Conference presentation be available?
Where can investors watch PHAT's Guggenheim Conference presentation?
What type of meetings will PHAT management conduct at the Guggenheim Conference 2025?